In 2021, PD-1 blockade was approved by the FDA for patients with progressive metastatic solid tumors with a high tumor mutation burden (TMB-H; ≥10 mutations/Mb) who have no alternative treatment options (The ASCO Post) (1). Here, PDCD1 is linked to neoplasm.